Ernexa Therapeutics, Inc. (ERNA)
4.30
+0.14
(+3.24%)
USD |
NASDAQ |
Sep 14, 11:05
Ernexa Therapeutics Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2024 | -6.70K% |
| September 30, 2024 | 19.71% |
| June 30, 2024 | -1.33K% |
| March 31, 2024 | -1.18K% |
| December 31, 2023 | -3.12K% |
| September 30, 2023 | -1.15K% |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 41.47% |
| September 30, 2019 | 68.73% |
| June 30, 2019 | 65.44% |
| March 31, 2019 | 67.30% |
| December 31, 2018 | 64.15% |
| Date | Value |
|---|---|
| September 30, 2018 | 63.52% |
| June 30, 2018 | 64.25% |
| March 31, 2018 | 64.36% |
| December 31, 2017 | 65.52% |
| September 30, 2017 | 68.93% |
| June 30, 2017 | 69.06% |
| March 31, 2017 | 63.09% |
| December 31, 2016 | 63.51% |
| September 30, 2016 | 66.01% |
| June 30, 2016 | 63.94% |
| March 31, 2016 | 60.78% |
| December 31, 2015 | 46.79% |
| September 30, 2015 | 45.44% |
| June 30, 2015 | 43.45% |
| March 31, 2015 | 51.62% |
| December 31, 2014 | 45.23% |
| September 30, 2014 | 59.75% |
| June 30, 2014 | 56.98% |
| March 31, 2014 | 58.21% |
| December 31, 2013 | 56.71% |
| September 30, 2013 | 69.07% |
| June 30, 2013 | 69.90% |
| March 31, 2013 | 64.05% |
| December 31, 2012 | 72.22% |
| September 30, 2012 | 72.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Cerenome, Inc. | 63.26% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
| Savara, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -299.3% |
| Return on Assets | -168.1% |
| Return on Invested Capital | -268.2% |
| Return on Net Operating Assets | -698.3% |